|Protocol #||Sponsor||Protocol Title|
|A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination with Bevacizumab Versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma|
Kidney cancer has been notoriously resistant to conventional chemotherapy and radiation therapy. The most common types of kidney cancer are now treatable with a variety of angiogenesis-directed therapies, including Avastin, Sutent, Nexavar, Votrient, and Inlyta, or mTOR-directed therapies (Torisel and Afinitor). Immunotherapy, previously with Interleukin and Interferon, showed activity, but with significant toxicity.
Current trials are examining investigational PD1/ PDL-1 inhibitor immunotherapies alone or in combination with angiogenesis inhibitors.